Felipe Garcia

List of Publications by Citations

Source: https://exaly.com/author-pdf/1272905/felipe-garcia-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

317 papers	10,275 citations	47 h-index	87 g-index
351 ext. papers	13,042 ext. citations	5.6 avg, IF	5.87 L-index

#	Paper	IF	Citations
317	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *New England Journal of Medicine*, **2021**, 384, 497-511	59.2	1158
316	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *New England Journal of Medicine*, **2021**, 384, 1503-1516	59.2	374
315	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clinical Microbiology and Infection*, **2021**, 27, 83-88	9.5	280
314	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *Aids*, **2010**, 24, 123-37	3.5	270
313	COVID-19 in patients with HIV: clinical case series. *Lancet HIV,the*, **2020**, 7, e314-e316	7.8	268
312	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. *Aids*, **1999**, 13, F79-86	3.5	200
311	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 13747-52	11.5	176
310	A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. *Science Translational Medicine*, **2013**, 5, 166ra2	17.5	168
309	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA - Journal of the American Medical Association*, **2021**, 326, 499-518	27.4	154
308	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. *Aids*, **2001**, 15, F29-40	3.5	138
307	Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. *Aids*, **2006**, 20, 59-66	3.5	133
306	Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. *Journal of Infectious Diseases*, **2005**, 191, 1680-5	7	133
305	Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 36, 702-13	3.1	132
304	A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Archives of Internal Medicine*, **2003**, 163, 1220-6		129
303	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 522-532	35.1	112
302	Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). *PLoS ONE*, **2013**, 8, e52845	3.7	111
301	Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. *Clinical Infectious Diseases*, **2004**, 38, 565-71	11.6	102

300	Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. *Journal of Infectious Diseases*, **2002**, 186, 922-31	7	102
299	HIV and syphilis: when to perform a lumbar puncture. *Sexually Transmitted Diseases*, **2007**, 34, 141-4	2.4	100
298	Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. *Lancet, The*, **1998**, 352, 1194-5	40	91
297	Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. *HIV Medicine*, **2007**, 8, 251-8	2.7	91
296	Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clinical Infectious Diseases*, **2009**, 48, 1138-51	11.6	90
295	A therapeutic dendritic cell-based vaccine for HIV-1 infection. *Journal of Infectious Diseases*, **2011**, 203, 473-8	7	89
294	Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. *Diagnostic Microbiology and Infectious Disease*, **2006**, 56, 153-60	2.9	86
293	A nosocomial outbreak of influenza during a period without influenza epidemic activity. *European Respiratory Journal*, **2003**, 21, 303-7	13.6	86
292	Cellular immune responses and changes in VL after a Dendritic Cells (DC)-based therapeutic vaccine in cART treated chronic HIV-infected patients with CD4 T cells above 450/mm. *Retrovirology*, **2012**, 9, O42	3.6	78
291	Measuring quality of life among people living with HIV: a systematic review of reviews. *Health and Quality of Life Outcomes*, **2017**, 15, 220	3	77
290	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. *Lancet Infectious Diseases, The*, **2014**, 14, 291-300	25.5	76
289	Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. *Aids*, **2000**, 14, 1921-33	3.5	69
288	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). *Vaccine*, **2011**, 29, 8309-16	4.1	64
287	Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 36, 823-30	3.1	63
286	mHealth Interventions To Support Self-Management In HIV: A Systematic Review. *Open AIDS Journal*, **2017**, 11, 119-132	0.6	63
285	Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. *Clinical Infectious Diseases*, **2012**, 54, 1364-72	11.6	53
284	A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study. *PLoS ONE*, **2011**, 6, e14515	3.7	53
283	Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. *Current Pharmaceutical Design*, **2011**, 17, 1323-32	3.3	52

282	The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. *Journal of Virology*, **2011**, 85, 11468-78	6.6	52
281	Manic syndrome associated with efavirenz overdose. *Clinical Infectious Diseases*, **2001**, 33, 270-1	11.6	52
280	Rate and predictors of progression in elite and viremic HIV-1 controllers. *Aids*, **2016**, 30, 1209-20	3.5	51
279	Therapeutic vaccines against HIV infection. *Human Vaccines and Immunotherapeutics*, **2012**, 8, 569-81	4.4	50
278	Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. *Aids*, **1999**, 13, 1491-6	3.5	50
277	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. *Aids*, **2018**, 32, 2533-2545	3.5	50
276	Dendritic cell based vaccines for HIV infection: the way ahead. *Human Vaccines and Immunotherapeutics*, **2013**, 9, 2445-52	4.4	49
275	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. *Aids*, **2008**, 22, 2461-9	3.5	49
274	Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. *Lancet, The*, **2004**, 364, 65-7	40	49
273	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1833-42	5.1	47
272	Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. *Aids*, **2020**, 34, 1775-1780	3.5	47
271	Overview of SARS-CoV-2 infection in adults living with HIV. *Lancet HIV,the*, **2021**, 8, e294-e305	7.8	46
270	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. *Aids*, **2013**, 27, 181-9	3.5	44
269	Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	43
268	Definition of advanced age in HIV infection: looking for an age cut-off. *AIDS Research and Human Retroviruses*, **2012**, 28, 1000-6	1.6	43
267	Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. *Journal of Leukocyte Biology*, **2007**, 82, 1143-6	6.5	43
266	Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. *AIDS Research and Therapy*, **2011**, 8, 22	3	42
265	Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. *Journal of Leukocyte Biology*, **2011**, 89, 127-36	6.5	42

264	Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 35, 343-50	3.1	42
263	Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. *Clinical Infectious Diseases*, **2005**, 41, 1350-4	11.6	41
262	Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors. *PLoS ONE*, **2014**, 9, e106360	3.7	40
261	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. *Diagnostic Microbiology and Infectious Disease*, **2008**, 62, 34-43	2.9	40
260	Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. *Modern Pathology*, **2005**, 18, 127-36	9.8	40
259	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. *Modern Pathology*, **2017**, 30, 745-760	9.8	39
258	Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. *Clinical Infectious Diseases*, **2009**, 48, 1467-70	11.6	39
257	Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. *Journal of Infectious Diseases*, **2007**, 196, 1191-201	7	39
256	Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. *HIV Medicine*, **2013**, 14, 273-83	2.7	37
255	Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm. *AIDS Research and Human Retroviruses*, **2013**, 29, 1161-7	1.6	37
254	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. *Aids*, **2011**, 25, 27-36	3.5	37
253	Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. *Antiviral Therapy*, **2012**, 17, 1-8	1.6	37
252	Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. *Biomaterials*, **2010**, 31, 8749-58	15.6	37
251	A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. *Aids*, **2003**, 17, 43-51	3.5	37
250	Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. *Clinical Infectious Diseases*, **2005**, 41, 883-90	11.6	37
249	Coronavirus Disease 2019 in Pregnancy: A Clinical Management Protocol and Considerations for Practice. *Fetal Diagnosis and Therapy*, **2020**, 47, 519-528	2.4	36
248	Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. *Aids*, **2010**, 24, 2029-39	3.5	36
247	Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. *Clinical Infectious Diseases*, **2006**, 43, 79-89	11.6	36

246	Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. *Journal of NeuroVirology*, **2005**, 11 Suppl 3, 72-82	3.9	36
245	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. *Journal of Virology*, **2018**, 92,	6.6	36
244	Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. *Journal of Virology*, **2011**, 85, 5804-13	6.6	35
243	Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. *Aids*, **2000**, 14, 2485-94	3.5	35
242	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. *Aids*, **1999**, 13, 2377-88	3.5	35
241	Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. *Journal of Clinical Microbiology*, **2012**, 50, 407-13	9.7	34
240	Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 36, 791-9	3.1	34
239	Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. *PLoS ONE*, **2010**, 5, e9436	3.7	34
238	Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. *EBioMedicine*, **2019**, 42, 86-96	8.8	33
237	Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. *European Respiratory Journal*, **2001**, 17, 87-93	13.6	33
236	Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. *Biomaterials*, **2016**, 75, 327-339	15.6	32
235	The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. *Liver Transplantation*, **2009**, 15, 1133-41	4.5	32
234	Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 x 10(6)/l. *Aids*, **1997**, 11, 53-7	3.5	32
233	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. *PLoS Pathogens*, **2015**, 11, e1005270	7.6	31
232	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *International Journal of Epidemiology*, **2012**, 41, 1807-20	7.8	31
231	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. *Aids*, **2009**, 23, 2485-95	3.5	30
230	Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. *PLoS ONE*, **2011**, 6, e19644	3.7	30
229	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. *Aids*, **2015**, 29, 675-81	3.5	29

228	HIV-1 infected patients older than 50 years. PISCIS cohort study. *Journal of Infection*, **2008**, 57, 64-71	18.9	29
227	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. *Journal of Virology*, **2015**, 89, 9189-99	6.6	28
226	Analysis of Non-AIDS-Defining Events in HIV Controllers. *Clinical Infectious Diseases*, **2016**, 62, 1304-1309	11.6	28
225	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. *Vaccine*, **2011**, 29, 5250-9	4.1	28
224	Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature. *Clinical Microbiology and Infection*, **2003**, 9, 45-54	9.5	28
223	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. *Aids*, **2012**, 26, 1691-705	3.5	28
222	Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2018**, 14, 339-351	6	28
221	In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 577-86	5.1	27
220	Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. *Medicine (United States)*, **2006**, 85, 139-146	1.8	27
219	Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). *Aids*, **2017**, 31, 321-332	3.5	27
218	Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. *Journal of Virology*, **2010**, 84, 8141-52	6.6	26
217	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. *Clinical Infectious Diseases*, **2017**, 64, 621-628	11.6	26
216	Personalized therapy approach for hospitalized patients with COVID-19. *Clinical Infectious Diseases*, **2020**,	11.6	25
215	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. *European Respiratory Journal*, **2014**, 43, 166-77	13.6	25
214	Development of an mHealth platform for HIV Care: Gathering User Perspectives Through Co-Design Workshops and Interviews. *JMIR MHealth and UHealth*, **2018**, 6, e184	5.5	25
213	Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. *AIDS Research and Human Retroviruses*, **2009**, 25, 1249-59	1.6	24
212	Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 44, 132-8	3.1	24
211	Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. *Clinical Microbiology and Infection*, **2012**, 18, E485-90	9.5	23

210	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. *Aids*, **2012**, 26, 1829-34	3.5	23
209	Posterior mushroom keratoplasty in patients with Fuchs endothelial dystrophy and pseudophakic bullous keratopathy: transplant outcome. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2008**, 27, 673-8	3.1	23
208	Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. *Clinical Infectious Diseases*, **2000**, 30, 392-4	11.6	23
207	Endothelial cell activation in muscle biopsy samples is related to clinical severity in human cerebral malaria. *Journal of Infectious Diseases*, **1999**, 179, 475-83	7	23
206	New challenges in therapeutic vaccines against HIV infection. *Expert Review of Vaccines*, **2017**, 16, 587-600	5.2	22
205	pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 787-801	5.5	22
204	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. *Nature Communications*, **2019**, 10, 3705	17.4	21
203	Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects. *Clinical Immunology*, **2009**, 131, 374-84	9	21
202	Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. *Immunology*, **2009**, 128, 393-404	7.8	21
201	Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. *Immunology and Cell Biology*, **2009**, 87, 634-9	5	21
200	Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. *Clinical Infectious Diseases*, **2004**, 39, 569-74	11.6	21
199	Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. *Immunogenetics*, **2005**, 57, 644-54	3.2	21
198	Transmission of hepatitis C virus by discarded-needle injury. *Clinical Infectious Diseases*, **2005**, 41, 129-30	11.6	21
197	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. *HIV Medicine*, **2019**, 20, 237-247	2.7	20
196	IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. *Journal of Infectious Diseases*, **2013**, 207, 651-5	7	20
195	Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. *Vaccine*, **2012**, 30, 3703-9	4.1	20
194	Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. *Antiviral Therapy*, **2012**, 17, 337-46	1.6	20
193	An integral care telemedicine system for HIV/AIDS patients. *International Journal of Medical Informatics*, **2006**, 75, 638-42	5.3	20

192	Biphasic decline of CD4 cell count during scheduled treatment interruptions. *Aids*, **2005**, 19, 439-41	3.5	20
191	Comparison of T-Cell SubsetsPReconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 25, 296-305	3.1	20
190	A butterfly vertebra or a wedge fracture?. *International Orthopaedics*, **1993**, 17, 7-10	3.8	20
189	Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. *PLoS ONE*, **2012**, 7, e51287	3.7	20
188	Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. *Vaccine*, **2013**, 31, 3668-74	4.1	19
187	Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions. *PLoS ONE*, **2014**, 9, e116226	3.7	19
186	Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. *Vaccine*, **2014**, 32, 6266-76	4.1	19
185	Immunologic Reconstitution After 1 Year of Highly Active Antiretroviral Therapy, With or Without Protease Inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 29, 429-434	3.1	19
184	Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. *International Journal of Infectious Diseases*, **2021**, 104, 164-168	10.5	19
183	Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients. *AIDS Research and Human Retroviruses*, **2013**, 29, 68-76	1.6	18
182	Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients. *Diagnostic Microbiology and Infectious Disease*, **2010**, 68, 60-5	2.9	18
181	Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors. *Journal of Infectious Diseases*, **2011**, 203, 810-3	7	18
180	Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. *BMC Medical Genetics*, **2010**, 11, 63	2.1	18
179	Clarithromycin-induced acute psychoses in peptic ulcer disease. *European Journal of Clinical Microbiology and Infectious Diseases*, **1999**, 18, 70-1	5.3	18
178	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. *PLoS ONE*, **2015**, 10, e0145701	3.7	18
177	High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). *Aids*, **2002**, 16, 1554-6	3.5	18
176	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. *Trials*, **2019**, 20, 361	2.8	17
175	Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. *Clinical Infectious Diseases*, **2011**, 52, 662-70	11.6	17

174	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. *PLoS ONE*, **2015**, 10, e0141456	3.7	17
173	Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection		17
172	Unintended HIV-1 Infection During Analytical Therapy Interruption. *Journal of Infectious Diseases*, **2020**, 221, 1740-1742	7	17
171	Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. *Nanomedicine*, **2014**, 9, 2683-702	5.6	16
170	Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. *PLoS ONE*, **2011**, 6, e26009	3.7	16
169	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. *Aids*, **2008**, 22, 2481-92	3.5	16
168	Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections. *Vaccine Journal*, **2004**, 11, 608-14		16
167	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. *PLoS ONE*, **2016**, 11, e0155245	3.7	16
166	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. *Lancet Regional Health - Europe, The*, **2021**, 3, 100041		16
165	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. *Journal of Leukocyte Biology*, **2016**, 99, 349-59	6.5	15
164	Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. *BMC Nephrology*, **2017**, 18, 58	2.7	15
163	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010. *BMC Infectious Diseases*, **2013**, 13, 382	4	15
162	Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. *PLoS ONE*, **2014**, 9, e90710	3.7	15
161	Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations. *Journal of Virology*, **2013**, 87, 12227-36	6.6	15
160	Comparison of two HIV testing strategies in primary care centres: indicator-condition-guided testing vs. testing of those with non-indicator conditions. *HIV Medicine*, **2013**, 14 Suppl 3, 33-7	2.7	15
159	Non-myeloablative hematopoietic stem cell transplantation in the treatment of severe idiopathic CD4+ lymphocytopenia. *European Journal of Haematology*, **2011**, 87, 87-91	3.8	15
158	Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. *AIDS Research and Human Retroviruses*, **2010**, 26, 747-57	1.6	15
157	Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. *AIDS Research and Human Retroviruses*, **2006**, 22, 657-66	1.6	15

156	Comparison of T-cell subsetsPreconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 25, 296-305	3.1	15
155	Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1-Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 25, 26-35	3.1	15
154	Lymphoid tissue viral burden and duration of viral suppression in plasma. *Aids*, **2001**, 15, 1477-82	3.5	15
153	Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. *Aids*, **1998**, 12, 1285-9	3.5	15
152	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. *Journal of Infectious Diseases*, **2019**, 219, 867-876	7	15
151	The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. *Retrovirology*, **2017**, 14, 50	3.6	14
150	Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. *Clinical Microbiology and Infection*, **2013**, 19, 646-53	9.5	14
149	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). *Antiviral Research*, **2011**, 89, 19-25	10.8	14
148	Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 30, 364-6	3.1	14
147	Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients. *Aids*, **2017**, 31, 1895-1897	3.5	13
146	Sexually transmitted infections in young people and factors associated with HIV coinfection: an observational study in a large city. *BMJ Open*, **2019**, 9, e027245	3	13
145	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. *Journal of the International AIDS Society*, **2014**, 17, 19246	5.4	13
144	Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. *Clinical Pharmacokinetics*, **2005**, 44, 525-38	6.2	13
143	Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). *Enfermedades Infecciosas Y Microbiología Clínica*, **2006**, 24, 238-44	0.9	13
142	Quinine induced lupus-like syndrome and cardiolipin antibodies. *Annals of the Rheumatic Diseases*, **1996**, 55, 559-60	2.4	13
141	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. *Vaccines*, **2019**, 7,	5.3	13
140	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. *Chest*, **2017**, 152, 295-303	5.3	12
139	Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population. *BMJ Open*, **2018**, 8, e018533	3	12

138	Standard vaccines increase HIV-1 transcription during antiretroviral therapy. *Aids*, **2016**, 30, 2289-98	3.5	12
137	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2015**, 69, 206-15	3.1	12
136	Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 29, 429-34	3.1	12
135	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. *PLoS ONE*, **2017**, 12, e0184929	3.7	12
134	Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 46, 529-37	3.1	12
133	The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. *Immunology*, **2011**, 133, 318-28	7.8	11
132	Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection. *Aids*, **2002**, 16, 1761-5	3.5	11
131	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. *PLoS ONE*, **2017**, 12, e0186602	3.7	11
130	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. *BMC Medicine*, **2018**, 16, 30	11.4	10
129	Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort. *HIV Medicine*, **2014**, 15, 86-97	2.7	10
128	Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. *Antiviral Therapy*, **2013**, 18, 161-70	1.6	10
127	Immune modulators and treatment interruption. *Current Opinion in HIV and AIDS*, **2008**, 3, 124-30	4.2	10
126	Immunosuppressive drugs as an adjuvant to HIV treatment. *Journal of Antimicrobial Chemotherapy*, **2004**, 53, 415-7	5.1	10
125	Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 37, 1276-81	3.1	10
124	Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. *Journal of Acquired Immune Deficiency Syndromes*, **1998**, 19, 55-60		10
123	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. *Lancet HIV,the*, **2021**, 8, e701-e710	7.8	10
122	Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. *Antiviral Therapy*, **2005**, 10, 423-9	1.6	10
121	HIV therapeutic vaccine enhances non-exhausted CD4 T cells in a randomised phase 2 trial. *Npj Vaccines*, **2019**, 4, 25	9.5	9

120	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. *Clinical Microbiology and Infection*, **2018**, 24, 540-545	9.5	9
119	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. *International Journal of Tuberculosis and Lung Disease*, **2014**, 18, 700-8	2.1	9
118	Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. *PLoS ONE*, **2012**, 7, e48848	3.7	9
117	Laryngeal squamous cell carcinoma in HIV-positive patients: lack of association with human papillomavirus infection. *HIV Medicine*, **2009**, 10, 634-9	2.7	9
116	Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. *Vaccine*, **2009**, 27, 6166-78	4.1	9
115	HIV-1 upregulates intercellular adhesion molecule-1 gene expression in lymphoid tissue of patients with chronic HIV-1 infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 46, 268-74	3.1	9
114	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. *Enfermedades Infecciosas Y Microbiología Clínica*, **2017**, 35, 377-383	0.9	8
113	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). *Clinical Microbiology and Infection*, **2015**, 21, 105.e1-5	9.5	8
112	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1987-93	5.1	8
111	The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial. *Medicine (United States)*, **2016**, 95, e2673	1.8	8
110	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. *Aids*, **2015**, 29, 1493-504	3.5	8
109	Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. *Journal of Medical Virology*, **2003**, 70, 10-3	19.7	8
108	The EuroSIDA study: 25 years of scientific achievements. *HIV Medicine*, **2020**, 21, 71-83	2.7	8
107	Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling. *Journal of Immunological Methods*, **2017**, 442, 12-19	2.5	7
106	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. *HIV Medicine*, **2019**, 20, 264-273	2.7	7
105	Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation. *Immunology and Cell Biology*, **2016**, 94, 689-700	5	7
104	Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial. *AIDS Research and Human Retroviruses*, **2014**, 30, 425-33	1.6	7
103	Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. *Frontiers in Immunology*, **2017**, 8, 836	8.4	7

102	Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects. *Vaccine*, **2014**, 32, 5540-5	4.1	7
101	Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. *International Journal of Tuberculosis and Lung Disease*, **2013**, 17, 198-206	2.1	7
100	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. *BioMed Research International*, **2013**, 2013, 373601	3	7
99	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. *Vaccine*, **2011**, 29, 5711-24	4.1	7
98	Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients. *Immunotherapy*, **2009**, 1, 347-54	3.8	7
97	Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 184-8	5.1	7
96	Streptococcal myositis as a complication of juvenile dermatomyositis. *Neuromuscular Disorders*, **1991**, 1, 375-7	2.9	7
95	Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals. *PLoS ONE*, **2013**, 8, e58927	3.7	7
94	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/l. *Aids*, **2001**, 15, 131-3	3.5	7
93	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. *EBioMedicine*, **2020**, 57, 102830	8.8	7
92	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. *Journal of Microbiology, Immunology and Infection*, **2019**, 52, 667-671	8.5	7
91	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. *Clinical Microbiology and Infection*, **2015**, 21, 104.e1-5	9.5	6
90	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. *Clinical Infectious Diseases*, **2018**, 67, 958-961	11.6	6
89	Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1031-1038	5.1	6
88	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1982-6	5.1	6
87	A Role for Scavenger-like Lymphocyte Receptor CD6 in HIV-1 Viral Infection. *AIDS Research and Human Retroviruses*, **2014**, 30, A49-A50	1.6	6
86	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2857-2861	5.1	6
85	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. *Aids*, **2015**, 29, 1309-18	3.5	6

84	Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen. *HIV Medicine*, **2014**, 15, 547-56	2.7	6
83	Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection. *Viral Immunology*, **2012**, 25, 37-44	1.7	6
82	Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients. *AIDS Research and Human Retroviruses*, **2007**, 23, 863-7	1.6	6
81	Real-life use of remdesivir in hospitalized patients with COVID-19. *Revista Espanola De Quimioterapia*, **2021**, 34, 136-140	1.6	6
80	In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?. *Viruses*, **2021**, 13,	6.2	6
79	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. *Aids*, **2016**, 30, 553-62	3.5	6
78	Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV. *Journal of Controlled Release*, **2021**, 330, 1016-1033	11.7	6
77	Immune Restoration in HIV-Positive, Antiretroviral-Naive Patients after 1 Year of Zidovudine/Lamivudine plus Nelfinavir or Nevirapine. *Antiviral Therapy*, **2004**, 9, 197-204	1.6	6
76	Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention. *Sexually Transmitted Infections*, **2019**, 95, 238-243	2.8	5
75	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. *PLoS ONE*, **2019**, 14, e0220459	3.7	5
74	Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clinical Infectious Diseases*, **2015**, 60, 1262-8	11.6	5
73	Utilization of healthcare services by people living with HIV/AIDS in Europe. Eurosupport Group. *International Journal of STD and AIDS*, **2000**, 11, 784-9	1.4	5
72	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. *Revista Espanola De Quimioterapia*, **2021**, 34, 238-244	1.6	5
71	Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed. *Journal of Lipid Research*, **2018**, 59, 2108-2115	6.3	5
70	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.. *Scientific Reports*, **2022**, 12, 5250	4.9	5
69	Genotypic and Phenotypic Resistance Patterns in Early-Stage HIV-1-Infected Patients Failing Initial Therapy with Stavudine, Didanosine and Nevirapine. *Antiviral Therapy*, **2002**, 7, 283-287	1.6	5
68	Predictors of Tonsillar Tissue HIV-1 Viral Burden at Baseline and after 1 Year of Antiretroviral Therapy. *Antiviral Therapy*, **2003**, 8, 635-637	1.6	5
67	Effects of different antigenic stimuli on thymic function and interleukin-7/CD127 system in patients with chronic HIV infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 66, 466-72	3.1	4

66	Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue. *Journal of Virological Methods*, **2011**, 174, 69-76	2.6	4
65	Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country. *AIDS Patient Care and STDs*, **2012**, 26, 379-82	5.8	4
64	Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults. *HIV Medicine*, **2010**, 11, 535-9	2.7	4
63	Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption. *AIDS Research and Human Retroviruses*, **2008**, 24, 1485-95	1.6	4
62	Changes in HIV-1 RNA viral load following tuberculin skin test. *Journal of Acquired Immune Deficiency Syndromes*, **1998**, 18, 398-9		4
61	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. *Trials*, **2021**, 22, 808	2.8	4
60	Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study. *Frontiers in Immunology*, **2020**, 11, 586124	8.4	4
59	Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response. *Vaccines*, **2020**, 8,	5.3	4
58	Experience with the use of siltuximab in patients with SARS-CoV-2 infection. *Revista Espanola De Quimioterapia*, **2021**, 34, 337-341	1.6	4
57	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. *Clinical Infectious Diseases*, **2016**, 62, 1578-1585	11.6	4
56	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case-Control Study. *AIDS Research and Human Retroviruses*, **2016**, 32, 1016-1021	1.6	4
55	Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients. *Open Forum Infectious Diseases*, **2019**, 6, ofz485	1	4
54	Measuring empowerment among people living with HIV: a systematic review of available measures and their properties. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, **2019**, 31, 798-802	2.2	4
53	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. *Archivos De Bronconeumologia*, **2021**, 57, 79-82	0.7	4
52	High rates of long-term progression in HIV-1-positive elite controllers. *Journal of the International AIDS Society*, **2021**, 24, e25675	5.4	4
51	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. *PLoS ONE*, **2018**, 13, e0208345	3.7	4
50	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3296-3302	5.1	4
49	A Home Integral Telecare System for HIV/AIDS Patients. *Studies in Health Technology and Informatics*, **2005**, 114, 23-9	0.5	4

48	Metabolic and Immunological Effects of Antiretroviral Agents in Healthy Individuals Receiving Post-Exposure Prophylaxis. *Antiviral Therapy*, **2002**, 7, 195-197	1.6	4
47	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. *Transplant Infectious Disease*, **2017**, 19, e12724	2.7	3
46	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. *Lancet HIV,the*, **2019**, 6, e334-e340	7.8	3
45	Post-exposure prophylaxis for HIV infection in sexual assault victims. *HIV Medicine*, **2020**, 21, 43-52	2.7	3
44	Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals. *Nutrients*, **2021**, 13,	6.7	3
43	Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy. *Immunologic Research*, **2016**, 64, 1207-1215	4.3	3
42	Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. *Vaccines*, **2021**, 9,	5.3	3
41	Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. *Antiviral Therapy*, **2004**, 9, 197-204	1.6	3
40	Polymorphisms in the 3Puntranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. *Aids*, **2007**, 21, 891-3	3.5	2
39	Inmunoterapia y vacunas terap□ticas en la infecci□n por VIH. *Enfermedades Infecciosas Y Microbiolog□a Cl□nica*, **2005**, 23, 84-94	0.9	2
38	Retrospective analysis of antiretroviral HIV treatment success based on medical history or guided by the reverse hybridisation LiPA HIV genotyping system. *Journal of Medical Virology*, **2004**, 73, 151-7	19.7	2
37	Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. *Aids*, **2005**, 19, 829-31	3.5	2
36	Measles inclusion body encephalitis **2020**, 39, 148-151		2
35	Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study. *Journal of the International AIDS Society*, **2020**, 23, e25607	5.4	2
34	Platform encounters: A study of digitised patient follow-up in HIV care. *Sociology of Health and Illness*, **2021**, 43, 1117-1135	3	2
33	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine. *Vaccines*, **2021**, 9,	5.3	2
32	Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004-2016. *Journal of Immigrant and Minority Health*, **2019**, 21, 920-930	2.2	2
31	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. *BMJ Open*, **2021**, 11, e040775	3	2

30	Feasibility of using monocyte-derived dendritic cells obtained from cryopreserved cells for DC-based vaccines. *Journal of Immunological Methods*, **2021**, 498, 113133	2.5	2
29	Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy. *Antiviral Therapy*, **2003**, 8, 635-7	1.6	2
28	Cholangitis and pulmonary nodules in a clinical presentation of syphilis in an HIV-infected patient. *International Journal of STD and AIDS*, **2019**, 30, 820-824	1.4	1
27	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. *Frontiers in Immunology*, **2018**, 9, 1399	8.4	1
26	Immunotherapy and therapeutic vaccines in HIV infection. *Enfermedades Infecciosas Y Microbiología Clínica*, **2005**, 23, 95-104	0.9	1
25	Endocytosis by mature muscle cells of aggregates of parasitised erythrocytes and macrophages in severe malaria. *Lancet, The*, **1996**, 347, 1550-1	40	1
24	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. *Open Forum Infectious Diseases*, **2020**, 7, ofaa470	1	1
23	Temporal Data Mining of HIV Registries: Results from a 25 Years Follow-Up. *Lecture Notes in Computer Science*, **2009**, 56-60	0.9	1
22	Local barrier dysfunction identified by confocal laser endomicroscopy predicts bacterial translocation in HIV infection. *Aids*, **2020**, 34, 328-331	3.5	1
21	Differential miRNA plasma profiles associated with the spontaneous loss of HIV-1 control: miR-199a-3p and its potential role as a biomarker for quick screening of elite controllers. *Clinical and Translational Medicine*, **2021**, 11, e474	5.7	1
20	Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. *Vaccines*, **2019**, 7,	5.3	1
19	Efficiency of the EmERGE Pathway to provide continuity of care for Spanish people living with medically stable HIV. *Enfermedades Infecciosas Y Microbiología Clínica*, **2021**,	0.9	1
18	Multiple imputation approach for interval-censored time to HIV RNA viral rebound within a mixed effects Cox model. *Biometrical Journal*, **2019**, 61, 299-318	1.5	1
17	High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption. *Aids*, **2021**, 35, 2463-2468	3.5	1
16	Immunotherapy and therapeutic vaccines in HIV infection. *Enfermedades Infecciosas Y Microbiología Clínica*, **2005**, 23 Suppl 2, 84-104	0.9	1
15	A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 83, 479-485	3.1	0
14	Similar HIV-1 evolution and immunological responses at 10 years despite several therapeutic strategies and host HLA Types. *Journal of Medical Virology*, **2004**, 73, 495-501	19.7	0
13	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case-Control Study. *Infectious Diseases and Therapy*, **2021**, 10, 955-970	6.2	0

12	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. *HIV Medicine*, **2021**, 22, 218-224	2.7	0
11	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. *HIV Medicine*, **2021**, 22, 674-681	2.7	0
10	Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. *BMC Public Health*, **2021**, 21, 1596	4.1	0
9	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. *Frontiers in Immunology*, **2021**, 12, 767370	8.4	0
8	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.. *Infection*, **2022**, 1	5.8	0
7	Fusarium keratoplasticum infection in an HIV-infected patient. *International Journal of STD and AIDS*, **2018**, 29, 1039-1042	1.4	
6	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. *AIDS Research and Human Retroviruses*, **2014**, 30, A194-A194	1.6	
5	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)*, **2017**, 35, 377-383	0.1	
4	Pulmonary Infection Caused by in a Chronic HIV-Infected Individual Participating in a Therapeutic Vaccine Trial. *Vaccines*, **2021**, 9,	5.3	
3	Structured therapy interruptions (STIs): lessons from a therapeutic strategy **2004**, 115-126		
2	Pleural effusion as a manifestation of a Cryptococcal infection in an HIV patient. *Enfermedades Infecciosas Y Microbiología Clínica*, **2021**, 39, 524-524	0.9	
1	Pleural effusion as a manifestation of a Cryptococcal infection in an HIV patient. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)*, **2021**, 39, 524-526	0.1	